A phase 3 trial called SAFFRON is underway with savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR-mutated, MET-overexpressed, and/or amplified NSCLC with prior progression on osimertinib. This evidence concerns the gene MET and non-small cell lung carcinoma.